The growth of the EPS is critical in understanding the current valuation of BioPharmX Corporation. Common. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -100.00 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for BioPharmX Corporation. Common since it indicates how well the business is allocating resources to benefit shareholders.
BioPharmX Corporation. Common trades as part of the healthcare sector and is in the biotechnology industry. The company CEO is David S. Tierney. BioPharmX Corp is a specialty pharmaceutical company. It is engaged in utilizing its proprietary drug delivery technologies to develop and commercialize novel prescription and over-the-counter, products that address markets in health and dermatology.
Previous Intraday Performance:
The BPMX shares had a previous change of -4.52% which opened at 0.17 and closed at 0.16. It moved to an intraday high of 0.17 and a low of 0.16.
PR Newswire: BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance
Historical Performance:
Over the last five trading days, BPMX shares returned -5.87% and in the past 30 trading days it returned -11.08%. Over three months, it changed 0.25%. In one year it has changed 38.36% and within that year its 52-week high was 0.38 and its 52-week low was 0.10. BPMX stock is 60.50% above its 52 Week Low.
Our calculations result in a 200 day moving average of 0.21 and a 50 day moving average of 0.18. Right now, BPMX stock is trading -23.13% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
PR Newswire: BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance
Liquidity:
The company has a market cap of $30.7m with 191.5m shares outstanding and a float of 171.2m shares. Trading volume was 1,569,607 shares and has experienced an average volume of 2,299,746 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for BioPharmX Corporation. Common was -0.2 which ended on 31st of January 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.05.
Below was the last reported quarterly earnings per share:
07-31-2018: -0.02
04-30-2018: -0.02
01-31-2018: 0
10-31-2017: -0.05
Indicators Also to Watch:
Based on the latest filings, there is 10.70% of insider ownership and 10.90% of institutional ownership. Short-interest was 5,797,220, which was 3.03% of shares outstanding. The short-interest ratio or days-to-cover ratio was 2.23. This stock has some short interest, but it might be normal and no need to worry if long the position.
I calculated the beta to be -7.49
SeekingAlpha: Tracking Wallace Weitz’s Weitz Investment Management Portfolio – Q3 2018 Update
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -837.26%, return on assets is -257.62%, price-to-sales is 527.79 and price-to-book is 7.21.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
4 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: BioPharmX Corporation. Common, Biotechnology, BPMX, Healthcare
